Phase I trial with oral oxihumate in HIV-infected patients

Drug Development Research

Volumn 57, Issue 1, 2002, Pages 34-39

  Botes, Mariëtte E ^a   Dekker, J ^b   Van Rensburg, C E J ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b Enerkom (Pty) Ltd   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

HIV; Oxihumate; Phase I trial

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; HUMIC ACID; OXIHUMATE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

EID: 0036758538     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10117     Document Type: Article

References (12)

1. Bergh JJ, Cronje IJ, Dekker J, Dekker TG, Gerritsma LM, Mienie LJ. 1997. Non-catalytic oxidation of water-slurried coal with oxygen: Identification of fulvic acids and acute toxicity. Fuel 76:149-154.
2. Brandt H. 1964. Die behandlung degenerativer erkrankungen der wirbelsäule und der gelenke mit salizylierten huminsäurebädern. Fortschr Med 82:110.
3. Eichelsdörfer D. 1976. Moor in der heilkunde. In: Göttlich K, editor. Moor- und Torfkunde. Stuttgart: Schweizerbart.
4. Gramsch H. 1961. Ein beitrag zur behandlung der gastropathien. Med Monatsschr 15:658-687.
5. Klöcking R, Sprössig M, Witzler P, Thiel KD, Helbig B. 1983. Antiviral wirksam huminsäureähnliche polymere. Z Physiother 33:95-101.
6. Lopez-Fernandez MF, Blanco-Lopes MJ, Castineira MP, Batlle J. 1992. Further evidence for recessive inheritance of Von Willebrand disease with abnormal binding of Von Willebrand factor to factor VIII. Am J Hematol 40:20-27.
7. Reichert B. 1966. Huminsäuren und ihre derivate in der modernen therapie. Dtsch Apoth 18:204-206.
8. Scheider J, Weis, R, Manner C, Kary B, Werner A, Seubert BJ, Riede UN. 1996. Inhibition of HIV-1 in cell culture by synthetic humate analogues derived from hydroquinone: Mechanism of inhibition. Virology 218:389-395.
9. Soloveyva VP, Lotosh TD. 1984. Biologically active peat substancesbody resistance stimulators. Proc 7th Int Peat Congress, Dublin, 4. p 420-434.
10. Thiel KD, Klöcking R, Schweizer H, Sprössig M. 1977. Untersuchungen in vitro zur antiviralen aktivität von ammoniumhumat gegenüber herpes simplex-virus typ 1 und typ 2. Zbl Bakteriol Parasiten kd Infekt Kr u Hyg Abt 1 Org A 301-321.
11. Van Rensburg CEJ, Dekker J, Weis R, Smith T-L, Jansen van Rensburg E and Schneider J. 2002. Investigation of the anti-HIV properties of oxihumate. Chemotherapy 48:138-143.
12. Visser SA. 1973. Some biological effects of humic acids in the rat. Acta Biol Med Germ Band 31:569-581.